BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 25491139)

  • 1. Different expression of FoxM1 in human benign and malignant pleural effusion.
    Tang Z; Li H; Zhu H; Bai C
    Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
    Lee YC; Knox BS; Garrett JE
    Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
    Kuralay F; Tokgöz Z; Cömlekci A
    Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
    Liao ND; Lee WY
    Cancer Cytopathol; 2012 Aug; 120(4):269-75. PubMed ID: 22367930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
    Wei F; Wei Y; Li LF; Li GL; Wang GJ
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions.
    Wang M; Zhang Z; Wang X
    Clinics (Sao Paulo); 2014; 69(12):799-803. PubMed ID: 25627990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.
    Braunschweig T; Chung JY; Choi CH; Cho H; Chen QR; Xie R; Perry C; Khan J; Hewitt SM
    Diagn Pathol; 2015 May; 10():53. PubMed ID: 26022333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose transporter 1 protein detected by enzyme-linked immunosorbent assay and immunocytochemistry: a useful diagnostic tool for malignant pleural effusions.
    Liao ND; Chiang TA; Lee WY
    Cancer Cytopathol; 2013 Dec; 121(12):695-702. PubMed ID: 23861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic implications of telomerase activity in pleural effusions.
    Dikmen G; Dikmen E; Kara M; Sahin E; Doğan P; Ozdemir N
    Eur Respir J; 2003 Sep; 22(3):422-6. PubMed ID: 14516130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
    Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
    Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions.
    Xu F; Chen J; Shen HH; Wang XD; Shan J
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1286-9. PubMed ID: 15362202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.
    Fazli Khalaf F; Asadi Gharabaghi M; Balibegloo M; Davari H; Afshar S; Jahanbin B
    Int J Biol Markers; 2023 Jun; 38(2):81-88. PubMed ID: 36942429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
    Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
    Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H; Rona G; Hutter C; Bayer PM; Kummer F
    Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of three tumor markers determined in pleural effusions.
    Conejo JR; Benedito JE; Jimenez A; Menchen M; Cano J; Granizo V; Larrodera L
    Eur J Clin Chem Clin Biochem; 1996 Feb; 34(2):139-42. PubMed ID: 8833646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
    Alemán C; Manuel Porcel J; Ma Segura R; Alegre J; Esquerda A; Ruiz E; Bielsa S; de Sevilla TF
    Med Clin (Barc); 2009 Oct; 133(12):449-53. PubMed ID: 19783262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of LUNX mRNA and VEGF mRNA in pleural fluid for differentiating benign from malignant origin.
    Bao QL; Li J; Sun W; Jiang HG; Zhu LR; Wang Y
    Jpn J Clin Oncol; 2014 Dec; 44(12):1198-205. PubMed ID: 25425729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytochemistry and ELISA quantitation of mucin for diagnosis of malignant pleural effusions.
    Yang PC; Luh KT; Kuo SH; Wu CW
    Am Rev Respir Dis; 1992 Dec; 146(6):1571-5. PubMed ID: 1456577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.